

Docket No.: PA-0046 US

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on June 6, 2002.

By: Debbie Ellis
Printed: Debbie Ellis

RECEIVED

JUL 08 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

In re Application of: Stuart et al.

COPY OF PAPERS
ORIGINALLY FILED

Title: GENES REGULATED BY MYCN ACTIVATION

Serial No.: 10/084,817 Filing Date: February 25, 2002

Examiner: To Be Assigned Group Art Unit: 1645

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.


Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 6 June 2002



Lynn E. Murry, Ph.D.

Reg. No. 42,918

Direct Dial Telephone: (650) 845-4159

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PA-0046 US		10/084,817	
LIST OF REFERENCES CITED BY APPLICANTS				Applicant(s)			
Use several sheets if necessary)				Stuart et al.			
COPY OF PAPERS ORIGINALLY FILED				Filing Date		Group	
				February 25, 2002		TECH CENTER 160025	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Foreign Patent Documents							
							Translation
		Document	Date	Country	Class	Subclass	Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Prochownik, E.D. and M.E. VanAntwerp, "Differential patterns of DNA by myc and max proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 90: 960-964 (1993)					
	2	O'Hagan, R.C. et al., "Gene-target recognition among members of the Myc superfamily and implications for oncogenesis," <u>Nat. Genet.</u> , 24: 113-119 (2000) *					
	3	Hurlin, P.J. et al., "Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation," <u>EMBO J.</u> , 15: 2030 (1996) *					
	4	Matthay, K.K. et al., "TREATMENT OF HIGH-RISK NEUROBLASTOMA WITH INTENSIVE CHEMOTHERAPY, RADIOTHERAPY, AUTOLOGOUS BONE MARROW TRANSPLANTATION, AND 13-CIS-RETINOIC ACID," <u>N. Engl. J. Med.</u> , 341: 1165-1173 (1999)					
	5	Nesbit, C.E. et al., "MYC oncogenes and human neoplastic disease," <u>Oncogene</u> , 18: 3004-3016 (1999)					
	6	Takisawa, H. et al., "Eukaryotic DNA replication: from pre-replication complex to initiation complex," <u>Curr. Opin. Cell Biol.</u> , 12: 690-696 (2000)					
	7	Maiorano, D. et al., "Stepwise Regulated Chromatin Assembly of MCM2-7 Proteins," <u>J. Biol. Chem.</u> , 275: 8426-8431 (2000)					
	8	Tye, B.K., "MCM Proteins in DNA Replication," <u>Annu. Rev. Biochem.</u> , 68: 649-686 (1999)					
	9	Thömmes, P. and J.J. Blow, "The DNA Replication Licensing System," <u>Cancer Surv.</u> , 29: 75-90 (1997)					
Examiner			Date Considered				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.</p>							

• OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

Jul 08 2002

TECH CENTER 1600/2900

Examiner

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.